Table 4. Pre-chemotherapy platelet surface expression of P-selectin and activated GPIIb/IIIa, MPA formation and risk of VTE in 62 cancer patients.
Hazard ratios (HR) and 95 % confidence intervals (CI) for the increase per decile in each parameter are given.
| Activated via | Risk of VTE | ||
|---|---|---|---|
| HR (95 % CI) | P-value | ||
| P-selectin (%) | - | 0.92 (0.72–1.15) | 0.438 |
| PAR-1 | 0.73 (0.56–0.92) | 0.007 | |
| PAR-4 | 0.89 (0.70–1.12) | 0.307 | |
| GPVI | 0.77 (0.59–0.98) | 0.034 | |
| Activated GPIIb/IIIa (%) | - | 0.97 (0.77–1.23) | 0.817 |
| PAR-1 | 0.76 (0.57–0.97) | 0.025 | |
| PAR-4 | 0.90 (0.71–1.13) | 0.355 | |
| GPVI | 0.79 (0.59–1.02) | 0.065 | |
| MPA (%) | - | 0.88 (0.69–1.10) | 0.266 |
| PAR-1 | 0.78 (0.59–1.00) | 0.046 | |
| PAR-4 | 0.85 (0.66–1.07) | 0.169 | |
| GPVI | 0.79 (0.59–1.00) | 0.052 | |
PAR: protease-activated receptor; GP: glycoprotein; MPA: monocyte-platelet aggregates.